Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420914 · ClinicalTrials.gov registry record · Phase 3
Strategies for Transfusion of Platelets (SToP)
A Phase 3 study, sponsored by Hamilton Health Sciences Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 130
- Enrollment target
NCT00420914 is a Phase 3 study that was terminated before completion, run by Hamilton Health Sciences Corporation. The registered enrollment target is 130 participants.
The verdict
NCT00420914, a Phase 3 study, was terminated before completion, sponsored by Hamilton Health Sciences Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 130 participants
- Enrollment target
Study Summary
To evaluate the hemostatic efficacy of a low dose platelet transfusion strategy compared to a standard dose platelet transfusion strategy.
Interventions
- PROCEDURE low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2003-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00420914
The ClinicalTrials.gov registry entry for NCT00420914 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hamilton Health Sciences Corporation, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9) is the first listed.
NCT00420914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00420914 about?
NCT00420914 is a clinical study titled "Strategies for Transfusion of Platelets (SToP)". To evaluate the hemostatic efficacy of a low dose platelet transfusion strategy compared to a standard dose platelet transfusion strategy.
What is the current status of trial NCT00420914?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2003-10.
What interventions are being tested in trial NCT00420914?
The interventions under investigation include: low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9) (PROCEDURE).
Who is sponsoring clinical trial NCT00420914?
This trial is sponsored by Hamilton Health Sciences Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.